Document is current
Any future updates will be listed below
-
Authors
Grünwald, Viktor https://orcid.org/0000-0003-2083-7687
Eberhardt, Berit
Bex, Axel
Flörcken, Anne
Gauler, Thomas
Derlin, Thorsten
Panzica, Martin
Dürr, Hans Roland
Grötz, Knut Achim
Giles, Rachel H. https://orcid.org/0000-0001-9133-2008
von Falck, Christian
Graser, Anno
Muacevic, Alexander
Staehler, Michael https://orcid.org/0000-0002-4574-6522
- License Information
-
More Information
Article History
First Online: 14 June 2018
Competing interests
: V.G. has participated in advisory boards for Bristol Myer Squibb (BMS), Eisai, Ipsen, Novartis, Pfizer, and Roche, has received honoraria for compensation from BMS, Eisai, Ipsen, Novartis, Pfizer, and Roche, and has received travel grants from BMS, MSD Merck, Novartis, and Pfizer. B.E. has received honoraria and/or travel grants from Pfizer. Uronauten receives no grants from the pharmaceutical industry. A.B. has participated in advisory boards for BMS, Ipsen, Novartis, Pfizer, and Roche/Genentech. A.F. has received honoraria and/or travel grants from Bayer, Ipsen, and Pfizer. R.H.G. has participated in advisory boards for Ipsen and Pfizer and has received travel grants from Ipsen and Pfizer. A.G. has received honoraria and/or travel grants from Bayer, Novartis, and Pfizer. M.S. participated in advisory boards for AVEO, BMS, Eisai, EUSA Pharma, Exelixis, Ipsen, Novartis, Peloton, Pfizer, and Roche/Genentech, has received travel grants from Bayer, BMS, Eisai, Ipsen, Novartis, and Pfizer, and has received research grants from AVEO, BMS, Eisai, Exelixis, Ipsen, Novartis, Pfizer, and Roche/Genentech. The International Kidney Cancer Coalition (IKCC) receives grants from Global Offices of Ipsen/Exelixis, Merck/MDS, BMS, Pfizer, Novartis, and Eisai. T.G., T.D., M.P., H.R.D., K.A.G., C.v.F., and A.M. declare no competing interests.
